BW Gestao de Investimentos Ltda. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, Holdings Channel reports. The fund purchased 20,000 shares of the company’s stock, valued at approximately $2,588,000. Johnson & Johnson comprises approximately 1.0% of BW Gestao de Investimentos Ltda.’s holdings, making the stock its 13th biggest position.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Virtus ETF Advisers LLC bought a new stake in Johnson & Johnson in the 2nd quarter worth approximately $25,000. Krane Funds Advisors LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $26,000. Financial Advantage Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $28,000. Crewe Advisors LLC grew its position in shares of Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after acquiring an additional 196 shares during the period. Finally, Permanens Capital L.P. grew its position in shares of Johnson & Johnson by 50.0% during the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after acquiring an additional 100 shares during the period. 72.25% of the stock is owned by institutional investors.

JNJ opened at $133.00 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The firm’s fifty day moving average is $130.83 and its 200 day moving average is $134.05. The stock has a market cap of $343.25 billion, a price-to-earnings ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter in the previous year, the company earned $2.05 EPS. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 8.65 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.

A number of brokerages have recently issued reports on JNJ. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective for the company in a research report on Thursday, October 17th. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Wells Fargo & Co cut their price objective on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th. Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Finally, Bank of America reissued a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Buy” and an average price target of $151.64.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Why is the LIBOR significant?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.